The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation. “Historically, ...

Pfizer announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s BRAFTOVI® ...

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6. Patients were eligible for the study if ...

In BREAKWATER (previously untreated BRAF V600E mutation-positive mCRC), the incidence of Grade 3 or 4 increases in ... and thoracic cancers, which includes lung cancer. Driven by science, we are ...

for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. i The indication was approved based on a statistically ...

has announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and ...

Australian researchers have found a way to silence cancer-causing gene mutations In a new study researchers from Melbourne Peter MacCallum Cancer Ce ...

With today’s accelerated approval of the BRAFTOVI regimen, patients with metastatic colorectal cancer with a BRAF V600E mutation now have a first-line treatment option, which contains a targeted ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...